BioStock: Aptahem approaching milestone via oversubscribed rights issue

Biotechnology company Aptahem, that develops its drug candidate Apta-1 for the treatment of life-threatening organ and tissue damage caused by sepsis, was recently able to announce an oversubscribed rights issue that strengthens the company ahead of its continued development. At a subscription rate of 116 per cent, the company is now well equipped to carry out the planned final GLP toxicology studies with Apta-1.

Read the full article about Aptahem at biostock.se:

https://www.biostock.se/en/aptahem-approaching-milestone-via-oversubscribed-rights-issue/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se